Literature DB >> 23102557

Assessment of microbiota and peptidoglycan in perianal fistulas.

R S van Onkelen1, L E Mitalas, M P Gosselink, A van Belkum, J D Laman, W R Schouten.   

Abstract

Transanal advancement flap repair has been advocated as the treatment of choice for high transsphincteric perianal fistulas, but fails in 1 of every 3 patients. Persistence of the fistula after flap repair might be the result of ongoing disease in the remaining fistula tract. In 10 specimens of the distal part of the fistula, microbiota was assessed by means of conventional microbiological culture and 16S rRNA gene sequencing. Proinflammatory bacterial peptidoglycan and recognition proteins were assessed by immunohistochemistry. Bacterial species were bowel derived, skin derived, or a combination of both. No mycobacterium species were identified. 16S rRNA gene sequencing failed to identify bacteria in all but 1 specimen, most likely as a result of low numbers of organisms. Peptidoglycan was detected in 90% of the patients, and a host response to peptidoglycan in 60%. Therefore, we suggest that peptidoglycan might play a role in the ongoing inflammation in perianal fistulas.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23102557     DOI: 10.1016/j.diagmicrobio.2012.09.012

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  9 in total

Review 1.  Pathogenesis and persistence of cryptoglandular anal fistula: a systematic review.

Authors:  Jeremy Sugrue; Johan Nordenstam; Herand Abcarian; Amelia Bartholomew; Joel L Schwartz; Anders Mellgren; Philip J Tozer
Journal:  Tech Coloproctol       Date:  2017-06-15       Impact factor: 3.781

2.  Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease.

Authors:  Britta Siegmund; Roger M Feakins; Giorgos Barmias; Juliano Coelho Ludvig; Fabio Vieira Teixeira; Gerhard Rogler; Michael Scharl
Journal:  J Crohns Colitis       Date:  2015-12-17       Impact factor: 9.071

Review 3.  Treatments for the amelioration of persistent factors in complex anal fistula.

Authors:  Daniel P Fitzpatrick; Carmel Kealey; Damien Brady; Martin Goodman; Noel Gately
Journal:  Biotechnol Lett       Date:  2021-11-19       Impact factor: 2.461

4.  Pro-inflammatory cytokines in cryptoglandular anal fistulas.

Authors:  R S van Onkelen; M P Gosselink; M van Meurs; M J Melief; W R Schouten; J D Laman
Journal:  Tech Coloproctol       Date:  2016-07-11       Impact factor: 3.781

5.  Fistulizing Crohn's Disease.

Authors:  Michael Scharl; Gerhard Rogler; Luc Biedermann
Journal:  Clin Transl Gastroenterol       Date:  2017-07-13       Impact factor: 4.488

Review 6.  Current concepts in the pathogenesis of cryptoglandular perianal fistula.

Authors:  Marcin Włodarczyk; Jakub Włodarczyk; Aleksandra Sobolewska-Włodarczyk; Radzisław Trzciński; Łukasz Dziki; Jakub Fichna
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

Review 7.  Journey through Crohn's Disease Complication: From Fistula Formation to Future Therapies.

Authors:  Federica Rubbino; Luana Greco; Alessio di Cristofaro; Federica Gaiani; Stefania Vetrano; Luigi Laghi; Stefanos Bonovas; Daniele Piovani
Journal:  J Clin Med       Date:  2021-11-26       Impact factor: 4.241

8.  Human Amniotic Membrane for the Treatment of Cryptoglandular Anal Fistulas.

Authors:  Carlo Ratto; Ornella Parolini; Angelo Alessandro Marra; Valentina Orticelli; Angelo Parello; Paola Campennì; Veronica De Simone; Diletta Trojan; Francesco Litta
Journal:  J Clin Med       Date:  2022-03-01       Impact factor: 4.241

9.  Efficacy and safety of autologous adipose-derived stromal vascular fraction enriched with platelet-rich plasma in flap repair of transsphincteric cryptoglandular fistulas.

Authors:  W R Schouten; J H C Arkenbosch; C J van der Woude; A C de Vries; H P Stevens; G M Fuhler; R S Dwarkasing; O van Ruler; E J R de Graaf
Journal:  Tech Coloproctol       Date:  2021-10-04       Impact factor: 3.781

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.